A safety review committee for a first-in-human trial reviews accumulating safety, pharmacokinetic and other data at predefined points to decide whether to escalate the dose, repeat a dose level, expand a cohort, pause or stop. It works well when a written charter defines membership, data, decision rules, timing and documentation before the first participant is dosed.
How is a safety review committee different from a DSMB?
A safety review committee typically includes sponsor medical leadership and investigators and makes dose escalation decisions in early-phase studies. A data monitoring committee, often called a DSMB, is independent of the sponsor and is more common in later-phase or randomized trials, where it reviews unblinded interim data. Some programs use both at different stages.
Who should sit on the committee?
Voting members commonly include the sponsor's medical lead, the principal investigator or investigators, a clinical pharmacologist and a safety physician. A statistician may join when designs are model-based. Clinical operations and data management usually attend as non-voting members to support the process. Define voting membership and quorum in the charter.
What data does the committee review?
Adverse events and serious adverse events, dose-limiting toxicities as defined in the protocol, laboratory results, vital signs, ECGs, pharmacokinetic data and any sentinel dosing observations. The charter should specify the data cut-off, the cleaning standard expected before review and the format of the data package.
What decisions can it make?
Escalate to the next dose, repeat the current dose, de-escalate, expand a cohort, pause dosing or stop, all within the rules set by the protocol. The committee's role is to apply those rules thoughtfully, not to invent new ones on the fly.
What belongs in the charter?
Purpose and scope, membership and roles, meeting triggers, the contents and timing of data packages, decision rules, quorum, conflict of interest handling, documentation of minutes and decisions, communication of decisions to sites and a process for urgent ad hoc reviews.
What are the operational bottlenecks?
Data turnaround is almost always the limiting step. Plan how data move from sites into the database, how quickly pharmacokinetic results return from the laboratory and how long it takes to assemble a review package. Do a dry run with mock data before the first cohort. Use templates for packages and decision letters. And make sure every site receives the committee's decision in writing before dosing the next cohort.
Why does this matter for an emerging sponsor?
A first-in-human study is often a small company's first real test of its operating model. A well-run safety review committee protects participants, keeps escalation on schedule and shows investigators, regulators and investors that the company makes decisions carefully.
Keep reading: IND Readiness: The Operational Workstreams That Gate First Patient
